

# Erhan Keleş

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7756309/publications.pdf>

Version: 2024-02-01

8  
papers

96  
citations

1937457

4  
h-index

2272820

4  
g-index

8  
all docs

8  
docs citations

8  
times ranked

97  
citing authors

#	ARTICLE	IF	CITATIONS
1	Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted bloodâ€“brain barrier permeability. RSC Medicinal Chemistry, 2021, 12, 579-583.	1.7	6
2	Abstract 291: Development of optimized chemical probes targeting PI3Ka to deconvolute the role of class I PI3Ks isoforms in insulin signaling. , 2021, , .		0
3	Abstract 293: Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitors suitable for the treatment of CNS disorders. , 2021, , .		0
4	Abstract 1377: Volume scanning, a rational approach to covalent PI3KÎ± inhibitors. , 2021, , .		0
5	Abstract 1378: A novel, highly potent PI3KÎ± covalent inhibitor deconvolutes class I PI3K isoforms in cancer cells. , 2021, , .		0
6	4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>-3,5-dimethylmorpholino)-6-((<i>R</i>-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amino)-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders. Journal of Medicinal Chemistry, 2020, 63, 13595-13617.	2.9	17
7	Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethylâ€“Pyrimidine Moiety. ACS Medicinal Chemistry Letters, 2019, 10, 1473-1479.	1.3	28
8	(<i>S</i>-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. Journal of Medicinal Chemistry, 2019, 62, 6241-6261.	2.9	45